RY 172.7 -0.1792% SHOP 152.38 -3.7762% TD 74.49 -0.4144% ENB 58.66 0.2906% BN 80.21 0.2124% TRI 235.76 -0.7034% CNQ 42.27 -1.3305% CP 102.81 -2.4851% CNR 145.02 -0.9426% BMO 139.15 0.5855% BNS 77.045 -0.149% CSU 4497.2998 0.6756% CM 92.23 -0.335% MFC 43.28 0.8858% ATD 79.0 -1.1882% NGT 53.35 -1.8038% TRP 65.26 0.215% SU 49.61 -1.411% WCN 251.65 -0.2181% L 191.14 0.1205%
Last update at 2024-12-19T18:55:00Z
Danaher Gears Up to Report Q3 Earnings: What's in the Cards?
Fri 18 Oct 24, 03:46 PMExploring Analyst Estimates for Danaher (DHR) Q3 Earnings, Beyond Revenue and EPS
Thu 17 Oct 24, 01:15 PMDanaher to Benefit From Business Strength Amid Headwinds
Fri 11 Oct 24, 01:20 PMIs Danaher Corporation (NYSE:DHR) The Top Goldman Sachs Fund Manager Stock Pick?
Fri 04 Oct 24, 05:10 PMThe Zacks Analyst Blog Highlights McDonald's, Danaher, S&P Global, Twin Disc and Cato
Wed 02 Oct 24, 11:15 AMTop Stock Reports for McDonald's, Danaher & S&P Global
Tue 01 Oct 24, 09:13 PMCepheid Drives Danaher Corporation (DHR) Q2 2024 Success, Hedge Funds Rally Around the Stock
Mon 30 Sep 24, 08:50 AMDanaher Corporation (DHR): Why Are Billionaires Bullish on This Stock Right Now?
Fri 27 Sep 24, 06:53 AMDanaher Schedules Third Quarter 2024 Earnings Conference Call
Thu 19 Sep 24, 08:30 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 8292.00M | 7598.00M | 4495.00M | 3305.30M | 3292.80M |
| Minority interest | - | - | 11.00M | 11.30M | 12.30M |
| Net income | 7209.00M | 6433.00M | 3646.00M | 3008.20M | 2650.90M |
| Selling general administrative | 8516.00M | 8198.00M | 6896.00M | 5588.30M | 6472.10M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 18949.00M | 17952.00M | 12475.00M | 9983.70M | 11107.10M |
| Reconciled depreciation | 2222.00M | 2168.00M | 1775.00M | 1189.50M | 1307.70M |
| Ebit | 8688.00M | 7465.00M | 4231.00M | 3269.40M | 3450.20M |
| Ebitda | 10725.00M | 10100.00M | 6116.00M | 4609.90M | 4757.90M |
| Depreciation and amortization | 2037.00M | 2635.00M | 1885.00M | 1340.50M | 1307.70M |
| Non operating income net other | -185.00000M | 371.00M | 539.00M | 144.50M | 46.40M |
| Operating income | 8688.00M | 7465.00M | 4231.00M | 3269.40M | 3403.80M |
| Other operating expenses | 22783.00M | 21988.00M | 18053.00M | 14641.70M | 16489.20M |
| Interest expense | 211.00M | 238.00M | 275.00M | 108.60M | 157.40M |
| Tax provision | 1083.00M | 1251.00M | 849.00M | 873.00M | 641.90M |
| Interest income | 170.00M | 227.00M | 204.00M | 139.00M | 9.20M |
| Net interest income | -170.00000M | -227.00000M | -204.00000M | 30.40M | -148.20000M |
| Extraordinary items | 0.00000M | 86.00M | 0.00000M | 575.90M | 251.60M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1083.00M | 1251.00M | 849.00M | 873.00M | 641.90M |
| Total revenue | 31471.00M | 29453.00M | 22284.00M | 17911.10M | 19893.00M |
| Total operating expenses | 10261.00M | 10487.00M | 8244.00M | 6714.30M | 7703.30M |
| Cost of revenue | 12522.00M | 11501.00M | 9809.00M | 7927.40M | 8785.90M |
| Total other income expense net | -396.00000M | 133.00M | 264.00M | 35.90M | 37.20M |
| Discontinued operations | - | 86.00M | 86.00M | 575.90M | 244.60M |
| Net income from continuing ops | 7209.00M | 6347.00M | 3646.00M | 2432.30M | 2650.90M |
| Net income applicable to common shares | 7103.00M | 6269.00M | 3510.00M | 2939.80M | 2650.90M |
| Preferred stock and other adjustments | 106.00M | 164.00M | 136.00M | 68.40M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 84350.00M | 83184.00M | 76161.00M | 62081.60M | 47832.50M |
| Intangible assets | 20300.00M | 22843.00M | 21282.00M | 9749.70M | 11673.10M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1860.00M | 1664.00M | 1430.00M | 864.60M | 906.30M |
| Total liab | 34260.00M | 38007.00M | 36384.00M | 31799.70M | 19605.80M |
| Total stockholder equity | 50082.00M | 45167.00M | 39766.00M | 30270.60M | 28214.40M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 3854.00M | 3950.00M | 4130.00M | 2517.50M | 2391.70M |
| Common stock | 9.00M | 9.00M | 9.00M | 8.40M | 8.20M |
| Capital stock | 1677.00M | 3277.00M | 3277.00M | 1608.00M | 8.20M |
| Retained earnings | 39205.00M | 32827.00M | 27159.00M | 24166.30M | 25163.00M |
| Other liab | 5922.00M | 7699.00M | 7789.00M | 4711.80M | 5075.80M |
| Good will | 39752.00M | 41184.00M | 35420.00M | 22712.50M | 25906.00M |
| Other assets | 4459.00M | 3719.00M | 2395.00M | 923.40M | 5587.50M |
| Cash | 5995.00M | 2586.00M | 6035.00M | 19912.30M | 787.80M |
| Cash and equivalents | 5995.00M | 2586.00M | 6035.00M | 19912.30M | 787.80M |
| Total current liabilities | 8389.00M | 8140.00M | 7402.00M | 4932.10M | 4841.50M |
| Current deferred revenue | 1648.00M | 1613.00M | 1212.00M | 687.80M | 685.20M |
| Net debt | 13682.00M | 19590.00M | 15169.00M | 1816.80M | 8952.50M |
| Short term debt | 591.00M | 8.00M | 11.00M | 212.40M | 51.80M |
| Short long term debt | 591.00M | 8.00M | 11.00M | 212.40M | 51.80M |
| Short long term debt total | 19677.00M | 22176.00M | 21204.00M | 21729.10M | 9740.30M |
| Other stockholder equity | 12072.00M | 10090.00M | 9698.00M | 7564.60M | 5834.30M |
| Property plant equipment | 3956.00M | 3790.00M | 3262.00M | 2302.00M | 2511.20M |
| Total current assets | 15883.00M | 11648.00M | 13802.00M | 25596.60M | 7093.80M |
| Long term investments | - | - | - | 33.70M | 38.30M |
| Net tangible assets | -11638.00000M | -22128.00000M | -20204.00000M | -3791.20000M | -9364.70000M |
| Short term investments | - | - | - | - | - |
| Net receivables | 4918.00M | 4631.00M | 4045.00M | 3191.40M | 3489.60M |
| Long term debt | 19086.00M | 22168.00M | 21193.00M | 21516.70M | 9688.50M |
| Inventory | 3110.00M | 2767.00M | 2292.00M | 1628.30M | 1910.10M |
| Accounts payable | 2296.00M | 2569.00M | 2049.00M | 1514.40M | 1712.80M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 8.00M | 10.00M | 11.00M | 11.30M | 12.30M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -2872.00000M | -1027.00000M | -368.00000M | -3068.30000M | -2791.10000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 9.00M | 9.00M | 9.00M | 8.40M | 8.20M |
| Preferred stock total equity | 1668.00M | 3268.00M | 3268.00M | 1599.60M | - |
| Retained earnings total equity | 39205.00M | 32827.00M | 27159.00M | 24166.30M | 25163.00M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 4459.00M | 3719.00M | 2395.00M | 1720.80M | 648.40M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 68467.00M | 71536.00M | 62359.00M | 36485.00M | 40738.70M |
| Capital lease obligations | 1062.00M | 1096.00M | 974.00M | 796.90M | - |
| Long term debt total | 19086.00M | 22168.00M | 21193.00M | 21516.70M | 9688.50M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2234.00000M | -808.00000M | -329.00000M | -241.00000M | -126.70000M |
| Change to liabilities | 81.00M | 320.00M | 372.00M | 422.60M | 216.90M |
| Total cashflows from investing activities | -2234.00000M | -12987.00000M | -21239.00000M | -1238.10000M | -2949.40000M |
| Net borrowings | -1688.00000M | 2063.00M | -1926.00000M | 13343.60M | -442.10000M |
| Total cash from financing activities | -2570.00000M | 1295.00M | 1006.00M | 16365.90M | -797.00000M |
| Change to operating activities | -2.00000M | 135.00M | 247.00M | 452.20M | 131.70M |
| Net income | 7209.00M | 6347.00M | 3646.00M | 2432.30M | 2650.90M |
| Change in cash | 3409.00M | -3449.00000M | -13877.00000M | 19124.50M | 157.70M |
| Begin period cash flow | 2586.00M | 6035.00M | 19912.00M | 787.80M | 630.30M |
| End period cash flow | 5995.00M | 2586.00M | 6035.00M | 19912.30M | 788.00M |
| Total cash from operating activities | 8519.00M | 8358.00M | 6208.00M | 3951.60M | 4022.00M |
| Issuance of capital stock | 31.00M | 86.00M | 3550.00M | 3816.30M | 96.00M |
| Depreciation | 2222.00M | 2168.00M | 1775.00M | 1189.50M | 1307.70M |
| Other cashflows from investing activities | -1082.00000M | 37.00M | -20119.00000M | -361.60000M | -2167.00000M |
| Dividends paid | 818.00M | 742.00M | 615.00M | 750.70M | 433.00M |
| Change to inventory | -486.00000M | -502.00000M | -123.00000M | -21.90000M | -143.30000M |
| Change to account receivables | -477.00000M | -611.00000M | -264.00000M | -156.40000M | -58.30000M |
| Sale purchase of stock | 934.00M | 3249.00M | 5704.00M | 16514.20M | 411.80M |
| Other cashflows from financing activities | -1752.00000M | -16.00000M | -3.00000M | -43.30000M | -364.00000M |
| Change to netincome | -223.00000M | 415.00M | 243.00M | 37.80M | -41.60000M |
| Capital expenditures | 1152.00M | 1294.00M | 791.00M | 635.50M | 584.00M |
| Change receivables | -477.00000M | -611.00000M | -264.00000M | -156.40000M | -58.30000M |
| Cash flows other operating | 7402.00M | 6530.00M | 4205.00M | 2480.00M | 2740.60M |
| Exchange rate changes | - | - | - | 45.10M | -117.70000M |
| Cash and cash equivalents changes | 3715.00M | -3334.00000M | -14025.00000M | 19124.50M | 157.50M |
| Change in working capital | -1519.00000M | -658.00000M | 605.00M | -123.20000M | -90.10000M |
| Stock based compensation | 336.00M | 218.00M | 187.00M | 158.80M | 151.40M |
| Other non cash items | 830.00M | 601.00M | 457.00M | 709.40M | 197.20M |
| Free cash flow | 7367.00M | 7064.00M | 5417.00M | 3316.10M | 3438.00M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DHR Danaher Corporation |
-0.38 0.17% | 227.92 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| TMO Thermo Fisher Scientific Inc |
2.81 0.54% | 518.99 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| IDXX IDEXX Laboratories Inc |
-0.4 0.10% | 410.36 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
| IQV IQVIA Holdings Inc |
-0.225 0.12% | 190.75 | 37.82 | 19.68 | 2.76 | 7.20 | 3.61 | 17.03 |
| A Agilent Technologies Inc |
0.86 0.65% | 133.87 | 31.97 | 25.84 | 6.23 | 6.96 | 6.62 | 23.01 |
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, municipal, industrial, and natural resource applications. It also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. The company was founded in 1969 and is headquartered in Washington, the District of Columbia.
2200 Pennsylvania Avenue, NW, Washington, DC, United States, 20037-1701
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven M. Rales | Co-Founder & Chairman | 1951 |
| Mr. Rainer M. Blair | Pres, CEO & Director | 1964 |
| Mr. Mitchell P. Rales | Co-Founder & Director | 1957 |
| Mr. Matthew R. McGrew | CFO & Exec. VP | 1972 |
| Ms. Angela S. Lalor | Part Time Advisor | 1965 |
| Mr. Joakim Weidemanis | Exec. VP | 1969 |
| Ms. Jennifer L. Honeycutt | Exec. VP | 1970 |
| Mr. Christopher M. Bouda | Chief Accounting Officer | NA |
| Dr. Jose-Carlos Gutierrez-Ramos Ph.D. | Sr. VP & Chief Science Officer | 1964 |
| Mr. John Bedford | VP of Investor Relations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...